C
365270
vs
K
KOSPI 200
Over the past 12 months, Curacle Co Ltd has outperformed KOSPI 200, delivering a return of +173% compared to the KOSPI 200's +118% growth.
Stocks Performance
365270 vs KOSPI 200
Performance Gap
365270 vs KOSPI 200
Performance By Year
365270 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Curacle Co Ltd
Glance View
Curacle Co., Ltd. is engaged in the business of research and experimental development on medical sciences and pharmacy. The company is headquartered in Seoul, Seoul and currently employs 39 full-time employees. The company went IPO on 2021-07-22. The firm researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.
